Sympagesic 500 mg/ml + 4 mg/ml Solution for Injection for Horses, Cattle, Pigs and Dogs

Land: Storbritannien

Språk: engelska

Källa: VMD (Veterinary Medicines Directorate)

Aktiva substanser:

Hyoscine Butylbromide, Metamizole sodium monohydrate

Tillgänglig från:

Dechra Regulatory BV

ATC-kod:

QA03DB04

INN (International namn):

Hyoscine Butylbromide, Metamizole sodium monohydrate

Läkemedelsform:

Solution for injection

Receptbelagda typ:

POM-V - Prescription Only Medicine – Veterinarian

Terapeutisk grupp:

Cattle, Dogs, Horses, Pigs

Terapiområde:

Neurological Agent muscle relaxant

Bemyndigande status:

Authorized

Tillstånd datum:

2019-05-21

Produktens egenskaper

Unlimited Renewal: August 2023
AN: 01489/2023
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Sympagesic 500 mg/ml + 4 mg/ml solution for injection for horses,
cattle, pigs and
dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCES:
Metamizole sodium monohydrate
500.0 mg
(equivalent to 443 mg metamizole)
Hyoscine butylbromide
4.0 mg
(equivalent to 2.76 mg hyoscine)
EXCIPIENTS:
Phenol
5.0 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, yellowish solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses, cattle, pigs, dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Horses, cattle, pigs, dogs: treatment of smooth muscle spasms and pain
associated
with underlying disorders of the gastro-intestinal tract, urogenital
system and bile
excretory organs.
Horses only: Spasmodic colics.
Cattle, pigs, dogs: Supportive therapy for acute diarrhoea and
gastroenteritis.
4.3
CONTRAINDICATIONS
Do not use in case of hypersensitivity to the active substances or to
any of the
excipients.
Unlimited Renewal: August 2023
AN: 01489/2023
Page 2 of 6
Do not use in cases of:
- gastro-intestinal ulceration
- chronic gastro-intestinal disorders
- mechanic obstruction in the gastro-intestinal system
- paralytic ileus
- disorders of the haematopoietic system
- coagulopathies
- renal insufficiency
- tachyarrhythmia
- glaucoma
- prostate adenoma.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Due to the risk of anaphylactic shock, metamizole-containing solutions
should be
administered slowly when given intravenously.
Special precautions to be taken by the person administering the
veterinary medicinal
product to animals
In a very small number of people, metamizole can cause reversible, but
potentially
serious agranulocytosis and other reactions such as skin allergy. Take
care to avoid
self-injection.
In case of accidental self-inje